Vitality Watch

Dossier pubmed observational 01-oct-2026
Human cohort, case-control, or epidemiological association

A Mendelian randomization study reveals TNF-β as a potential protective factor against sarcopenia.

Key claim: Mendelian randomization identifies circulating tumor necrosis factor-beta (TNF-β) as a protective causal factor against sarcopenia traits including appendicular lean mass, grip strength, and walking pace.

Abstract

Sarcopenia, defined by the loss of muscle mass and strength, significantly impacts the elderly and is linked to chronic inflammation. The exact causal relationship between circulating inflammatory factors and sarcopenia is not yet clear. We employed a 2-sample Mendelian randomization analysis using 91 circulating inflammatory factors as exposures and 4 sarcopenia traits as outcomes to explore potential causality. Our analysis confirmed a significant causal association between circulating inflammatory factors and sarcopenia. Specifically, tumor necrosis factor-beta was significantly associated with all sarcopenia traits (appendicular lean mass: P < .001, odds ratio [OR] = 1.023; left grip strength: P < .001, OR = 1.010; right grip strength: P = .001, OR = 1.008; walking pace: P = .017, OR = 1.004), supported by Bonferroni correction and multiple sensitivity analyses. Tumor necrosis factor-beta has emerged as a critical protective factor for sarcopenia, suggesting that targeting its levels may influence treatment approaches. This study emphasized the role of inflammatory pathways in sarcopenia and demonstrated the utility of Mendelian randomization in identifying these associations.

Why this matters

Inflammaging is usually written as a monolithic pro-aging force on muscle, but Mendelian randomization across 91 inflammatory factors picks out TNF-β as directionally protective for lean mass, grip strength, and walking pace. That refines the causal picture: individual cytokines within the inflammaging milieu can carry opposite signs for sarcopenia, and genetic-instrument evidence puts TNF-β on the protective side rather than the damage side.

Source

Link

Briefing card

A Mendelian randomization study reveals TNF-&#x3b2; as a potential protective factor against sarcopenia.
Stage: observational · pubmed · 01-oct-2026

Applies to researchers mapping which inflammatory cytokines causally drive sarcopenia — TNF-β emerges as protective, not pathogenic, in genetic-instrument analysis.

Mendelian randomization identifies circulating tumor necrosis factor-beta (TNF-β) as a protective causal factor against sarcopenia traits including appendicular lean mass, grip strength, and walking pace.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1097/MD.0000000000050951

build build 880 · 2bcef25 · 2026-11-18